EPS for MacroGenics, Inc. (MGNX) Expected At $-1.08 as of May, 2

April 20, 2018 - By Julia Strobel

Big Money Sentiment decreased to 1.11 in 2017 Q4. It has change of 0.47, from 2017Q3’s 1.58. The ratio is negative due to MacroGenics, Inc. positioning: 14 sold and 31 reduced. 15 funds took holdings and 35 increased holdings. Investors holded 27.72 million in 2017Q3 but now own 28.26 million shares or 1.97% more.
Great West Life Assurance Com Can holds 0% or 2,500 shs in its capital. The Nebraska-based Ameritas Inv Partners has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Pinnacle Assocs Ltd accumulated 0.3% or 816,975 shs. Baker Bros Advsrs Lp stated it has 363,676 shs. Fmr Ltd Company reported 3.64M shs. Mufg Americas Holding Corp reported 64 shs stake. Goldman Sachs Grp has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Dekabank Deutsche Girozentrale has invested 0.03% in MacroGenics, Inc. (NASDAQ:MGNX). Principal Financial Grp Inc reported 0% in MacroGenics, Inc. (NASDAQ:MGNX). Tiger Mngmt Ltd Llc reported 127,967 shs. Muhlenkamp & reported 10,515 shs. Wisconsin-based State Of Wisconsin Inv Board has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Jpmorgan Chase And owns 26,084 shs or 0% of their US capital. Renaissance Technologies Limited Liability Corp reported 0.01% in MacroGenics, Inc. (NASDAQ:MGNX). Federated Pa accumulated 0% or 778 shs.

MacroGenics, Inc. registered $1.30 million net activity with 0 buys and 8 sales since October 25, 2017. Karrels James sold $155,000 worth of MacroGenics, Inc. (NASDAQ:MGNX) or 5,000 shs on Monday, March 5. 10,000 shs valued at $200,000 were sold by Wigginton Jon Marc on Wednesday, October 25. On Wednesday, February 28 a trade for 23,967 shs valued at $599,436 was made by Cilinski Lynn.

MacroGenics, Inc. (NASDAQ:MGNX)’s quarterly earnings will be published On May, 2., according to RTT. Last year’s earnings per share was $-1.08, while now analysts expect change of 0.00 % from current $-1.08 earnings per share. -138.57 % negative EPS growth is what analysts predict. $2.80 earnings per share was published for last [previous quarter]. MGNX is reaching $23.56 during the last trading session, after decreased 2.08%.MacroGenics, Inc. has volume of 218,008 shares. Since April 20, 2017 MGNX has risen 31.18% and is uptrending. The stock outperformed the S&P500 by 19.63%.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

In total 8 analysts cover MacroGenics (NASDAQ:MGNX). “Buy” rating has 6, “Sell” are 0, while 2 are “Hold”. 75% are bullish. With $38 highest and $22 lowest [Target] MacroGenics has $30 average [Target] or 27.33% above the current ($23.56) price. 10 are the (NASDAQ:MGNX)’s analyst reports since October 25, 2017 according to StockzIntelligence Inc. On Wednesday, October 25 BTIG Research maintained the shares of MGNX in report with “Buy” rating. On Wednesday, March 14 the firm has “Equal-Weight” rating given by Morgan Stanley. On Friday, November 10 Citigroup maintained MacroGenics, Inc. (NASDAQ:MGNX) rating. Citigroup has “Neutral” rating and $22 target. On Tuesday, January 23 the company was maintained by SunTrust. On Friday, January 19 the firm earned “Buy” rating by BTIG Research. On Friday, April 6 Leerink Swann initiated MacroGenics, Inc. (NASDAQ:MGNX) with “Buy” rating. On Wednesday, October 25 the firm has “Buy” rating by Leerink Swann given.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States.The company has $994.18 million market cap. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.Currently it has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.